Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Assess the Safety and Efficacy of PTS100 in Primary Hepatocellular Carcinoma Patients Who Are Ineligible for Operation or Current Locoregional Therapy

NCT03447951 is registered in ClinicalTrials.gov with Gongwin Biopharm Co., Ltd. as lead sponsor.

NCT NCT03447951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03447951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Assess the Safety and Efficacy of PTS100 in Primary Hepatocellular Carcinoma Patients Who Are Ineligible for Operation or Current Locoregional Therapy
Lead sponsor
Gongwin Biopharm Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
June 19, 2018
Completion date
December 31, 2025
Enrollment
33 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma